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Introduction: Hepatoblastoma (HBL) is the most common primary liver 
tumor within childhood. Entire tumor resection is basis for ultimate cure 
for HBL and supports the only pleasant chance of long-standing disease-
free survival.
Objectives: In the current survey, we attempted to evaluate the long-term 
survival of children with HBL with surgical resection in a referral children 
hospital in Iran within the last decade. 
Materials and Methods: This retrospective descriptive study was 
conducted on all children who suffered HBL and undergone surgery 
between 2006 and 2016. Reviewing the recorded hospital files led to a 
sample of 30 eligible patients. The baseline characteristics of the patients 
were all collected by reviewing the files.
Results: In total, 30 consecutive children (21 male and 9 female) 
suffering HBL were described. Of those, 40.0% aged less than 12 months 
and only 6.7% aged higher than 36 months. The most common clinical 
manifestations were asymptomatic abdominal mass (in 66.7%) followed 
by fever (in 10.0%) and pain (in 10.0%). In more than half of the patients 
(53.3%), right lobe involved, while left lobe involved in 16.7%. based on 
histological report,marginal involvement was found in 75.0% of children, 
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Introduction
Hepatoblastoma (HBL) is the mainly primary liver 
tumor within infancy that regularly
identifies within the initial three years of life.1 
This tumor frequently appears sporadically, 
however, accompanying disease with some genetic 
abnormalities such as familial adenomatous 
polyposis or Beckwith-Wiedemann syndrome 
has been also described.2 Within the last decades, 
we have witnessed an increase in the incidence 
of the disease especially in very low birth 
weight children.3 HBL is commonly manifested 
by abdominal distension and mass as well as 
abdominal discomfort, loss of appetite and 
fatigue. In cases with tumor rupture, peritoneal 
irritation and severe anemia are prominent signs.4 
Diagnostic approach to HBL is based on clinical, 
laboratory and imaging studies. Elevated serum 
alpha-fetoprotein (AFP) is a good marker for 
suspecting HBL; however, it was not specific 
and might be increased in other tumors such as 
rhabdoid tumor.5 In ultrasonography assessment, 
it revealed as a huge mass in liver alongside with 
satellite tumors and regions of hemorrhage.6 The 
most sensitive modalities for detection of HBL 
are multiphase computed tomography (MPCT) 
or magnetic resonance imaging (MRI) reveal 
hyper-vascular lesions in the liver with delayed 
contrast excretion.7,8 Histological studies lead 
us to a definitive diagnosis especially in those 
children with low or moderate level of AFP.9 Some 
risk scoring systems are recommended to stratify 
the risk for HBL among children. The Children’s 
Hepatic Tumors International Collaboration 
(CHIC) risk stratification system classify the risk 
for HBL based on child’s age, the presence of distant 
metastases, portal vein conflict, hepatic vein/cava 
involvement, neighboring extra-hepatic cancer, 
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margin intact in 15.0% and margin free feature in 5.0%. Forty percent of 
children suffered from epithelial subtype of tumor, 20.0% from mixed 
epithelial and mesenchymal subtypes, and 13.3% from embryonal 
pattern. In total, 63.3% were scheduled for complete surgical resection 
followed by chemotherapy. Postoperatively, 40.0% of children remained 
free of complications, whereas postoperative bleeding occurred in 
20.0% and biloma in 40.0%. Overall, 76.9% of patients were completely 
cured, 7.7% suffered from pulmonary metastasis and 3.9% required liver 
transplantation. Postoperative death occurred in 11.5%. 
Conclusions: Considering surgical resection followed by chemotherapy 
leads to high cure rate, however a notable number of affected children 
suffer postoperative complication, requiring liver transplantation, 
pulmonary metastasis, or even non-survived emphasizing a serious review 




•  Liver tumor
3
Iranian Journal of Pediatric Surgery    Vol.7    No.1/2021
This open-access article is distributed under the terms of the Creative 
Commons Attribution Non Commercial 3.0 License (CC BY-NC 3.0).
Epidemiological, Clinical and Treatment in Hepatoblastoma     Mohajerzadeh et al
rupture identification, multifocality,elevated level 
of AFP, and pretreatment extent of disease.10 In 
the PRETEXT system, two components have been 
made as the PRETEXT group describing the extent 
of tumor within the liver and the annotation factors 
including the evidences of vascular involvement, 
multifocality, extra-hepatic involvement, tumor 
rupture and metastasis.11 Overall, the risk 
stratification for HBL is essential before treatment.
Currently, total tumor resection forHBL suggests 
the only reasonable possibility of long-standing 
disease-free survival.12 Within the last two 
decades, introducing chemotherapeutic protocol 
led to considerably decreasing postoperative 
recurrence rate.13 Besides, applying advanced 
surgical techniques have resulted in improving the 
prognosis of patients suffering HBL. In this regard, 
the arrangement of surgery and chemotherapy 
remains best selection for therapeutic strategy in 
HBLwith respect to achieving appropriate long-
term prognosis as well as increasing patients’ 
survival.14 In the current survey, we attempted to 
evaluate the long-term survival of children with 
HBL, with surgical resection at Mofid Children 
Hospital, a large referral children hospital in 
Iranwithin the last decade. 
Materials and Methods
This retrospective descriptive study was conducted 
on all children suffering from HBL and undergoing 
surgery between 2006 and 2016. Reviewing the 
recorded hospital files led to a number of 30 eligible 
patients. The baseline characteristics of the patients 
including gender, age, clinical manifestations, 
early postoperative outcome, procedure-related 
mortality, rate of requiring liver transplantation, 
rate of lung metastasis, pathological report 
related to definitive diagnosis of the disease, and 
disease stage, were all collected by reviewing 
the files. The disease staging was based on the 
2005 PRETEXT staging system that previously 
described.15 The study endpoint was to describe 
preoperative characteristics, histological findings 
and subtypes of tumor, tumor staging, considering 
concomitant neoadjuvant chemotherapy, as well 
as postoperative consequences regarding recovery 
rate, mortality, and surgical complications. In terms 
of ethical considerations, observance is trusted to 
review resources and articles. Personal information 
obtained from the patients was kept confidential 
and all information useful for the research was 
sought to be made available for use. All study 
protocols were approved by the ethical committee 
at Tehran University of Medical Sciences. 
Descriptive analysis employed to explain the 
data, counting mean ± standard deviation (SD) for 
quantitative variables and frequency (percentage) 
for categorical variables. Statistical analysis was 
employed with statistical software IBM SPSS 
Statistics version 22.0 (IBM Corp. Released 2013, 
Armonk, New York).
Results
In total, 30 consecutive children (21 male and 9 
female) suffering HBL were described. Of those, 
40.0% aged less than 12 months and only 6.7% 
aged higher than 36 months Table 1. Regarding 
stage of disease, 66.7% were classified at the stage 
II, 23.3% at the stage III and 3.3% at the stage 
IV and therefore, metastasis was revealed only in 
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3.3% of the participants. The most common clinical manifestations included asymptomatic abdominal mass 
(in 66.7%) followed by fever (in 10.0%) and pain (in 10.0%), while fatigue simultaneous with anorexia, 
weight loss and jaundice were found in 3.3% of affected children Table 1. 





0 to 12 12 (40.0)
13 to 24 9 (30.0)
25 to 36 6 (20.0)







Asymptomatic abdominal mass 20 (66.7)
Fever 3 (10.0)
Pain 3 (10.0)
Fatigue, anorexia, weight loss, jaundice 1 (3.3)
Asymptomatic abdominal mass, fatigue, anemia 1 (3.3)
Asymptomatic abdominal mass, anorexia, weight loss 1 (3.3)
Fatigue, fever 1 (3.3)
Regarding degree of liver involvement, in more 
than half of the patients (53.3%), right lobe 
involved, while left lobe involved in 16.7% and 
bilateral involvement was found in 3.3%. Also, 
midportion and central lobe involvement was 
revealed in 3.3% and 3.3% respectively. With 
respect to the degree of histological involvement, 
marginal involvement was found in 75.0% of 
children, margin intact in 15.0% and margin free 
feature in 5.0%. The different subtypes of HBL 
according to pathological assessment are shown 
in Figure 1. In total, 40.0% of children suffered 
from epithelial subtype of tumor, 20.0% from 
mixed epithelial and mesenchymal subtypes, 
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and 13.3% from embryonal pattern. Regarding 
therapeutic management, 63.3% were scheduled 
for complete surgical resection followed by 
chemotherapy. Also, surgical biopsy, neoadjuvant 
chemotherapy followed by complete surgical 
resection was planned for 13.3% of patients and 
percutaneous biopsy, neoadjuvant chemotherapy 
followed by complete surgical resection for 10.0%. 
Postoperatively, 40.0% of children remained free 
of complications, whereas postoperative bleeding 
occurred in 20.0% and biloma in 40.0%. Overall, 
76.9% of patients were completely cured, 7.7% 
suffered from pulmonary metastasis and 3.9% 
required liver transplantation. Postoperative death 
occurred in 11.5%. The characteristics of non-
cured patients are summarized in Table 2.
Table 2: Characteristics of non-cured group with hepatoblatoma
Event Sex/age Stage  Liver involvement
Lung metastasis
Case 1 F/24m IV Both lobes
Case 2 M/16m II Right lobe
Liver transplant
Case 1 F/8y IV Both lobes
Expired 
Case 1 F/12m II Left lobe
Case 2 M/18m III Right lobe
Case 3 M/5y II Left lobe
Figure 1: Histological subtypes of hepatoblastoma
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Discussion
As the first result, the incidence of HBL was 
considerably higher in male than in female children 
with the male to female ratio of 2.3 indicating 
higher tendency of disease to male individuals. 
Although some reports indicated a male: female 
ratio of 1.2 for HBL, in a large survey in the United 
States and the Europe showed a range of 1.3 to 
3.3 for male to female ratio indicating our sex 
distribution in global range.16-19 Regarding clinical 
manifestations, an asymptomatic abdominal mass 
was the prominent sign discovering in about two-
third of the patients, while other manifestations 
included fever, upper zone abdominal pain and 
rarely fatigue, anorexia, weight loss, and jaundice. 
The literature shows that the majority of cases may 
identify with an enlarged abdominal tumor that 
the right lobe is concerned three times compared 
with the left. In this regard, anorexia, weight loss, 
and pain were less common that was comparable 
with our observations.20, 21 In our study and 
regarding histological feature, 40.0% of children 
suffered from epithelial subtype of tumor, and 
20.0% from mixed epithelial and mesenchymal 
subtypes. It has been shown that HBL is classified 
as epithelial in about 56% or mixed epithelial/
mesenchymal in 44%. Also, epithelial type was 
also sub-classified to pure fetal in 31%, embryonal 
in 19%, macrotrabecular in 3%, and small cell un-
differentiated in less than 3%.22 It should be also 
noted that association of mesenchymal elements 
has been suggested with better prognosis in cases 
with extensive HBL.23 
With respect to the therapeutic management, 
all patients were planned for complete surgical 
resection followed by neoadjuvant chemotherapy 
led to a complete cure rate of 76.9% that was 
considered as acceptable treatment successfulness. 
However, the rate of postoperative complications as 
well as poor prognosis due to pulmonary metastasis 
or even death remains high. In our study, despite 
proper management of patients by a combination 
therapy plus chemotherapy, 11.5% of patients 
died, 7.7% suffered from pulmonary metastasis 
and 3.9% required liver transplantation. Entire 
resection of the tumor permits the most excellent 
expect for long-standing survival; on the other 
hand, the beginning of successful chemotherapy 
may allow healing despite metastatic disorder.
Chemotherapy showed to be efficient both in an 
adjuvant as well as neoadjuvant situation. The 
employ of neoadjuvant chemotherapy had been led 
to mainly no metastatic hepatoblastomas become 
resectable. This indicates that in spite of employing 
advanced surgical techniques and updated surgical 
approach, the prognosis of the treated patients 
remains partially poor yet.  Also, in our study, about 
half of the patients suffered from postoperative 
complications such as bleeding or biloma. Due 
to such surgery-related complications, selecting 
surgical approach for the treatment may not be first 
choice among majority of clinicians especially in 
advanced stages of disease. As shown by Seo et 
al.23, less complications were reported following 
preoperative chemotherapy, but complications 
were advanced, with second-look surgeries 
after an open incisional biopsy or cannulation 
of hepatic artery. One of the main complications 
of disease included lung metastasis revealing in 
7.7%. The majority site of distant metastasis for 
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HBL reported in the lungs. The violent approach 
to excision of pulmonary metastasis may lead in 
long-standing survival particularly in the presence 
of AFP <25ng/ml, early resection of metastasis, 
favorable response of metastasis to chemotherapy, 
and complete surgical resection of the tumor.24
Conclusion
In total, although we achieved high cure rate of 
76.9%, the rate of complications or unpredictable 
adverse outcome including pulmonary metastasis, 
requiring liver transplantation or even death 
showed that our treatment approach has not been 
completely successful needing modification of the 
current protocols. 
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